Search company, investor...
Search

Founded Year

2015

Stage

Series B | Alive

Total Raised

$220K

Last Raised

$70K | 1 yr ago

About Intrommune Therapeutics

Intrommune Therapeutics is a New York City-based biotechnology company dedicated to simplifying allergy immunotherapy. Intrommune’s core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste designed to incorporate and stabilize allergenic proteins, representing a therapeutic approach for the treatment of peanut and other food allergies. Intrommune’s mission is to develop safe and effective options for food allergy sufferers so they and their loved ones can live their lives without fear.

Intrommune Therapeutics Headquarters Location

20 W 125th St.

New York, New York, 10027,

United States

646-770-2533

Intrommune Therapeutics's Product Videos

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Intrommune Therapeutics's Products & Differentiation

See Intrommune Therapeutics's products and how their products differentiate from alternatives and competitors

  • INT301

    Oral Mucosal Immunotherapy to desensitize people with peanut allergy from having severe allergic reactions. INT301 utilizes a specially formulated toothpaste that optimizes exposure of allergenic proteins to a patients immune system, while cleaning their teeth

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Expert Collections containing Intrommune Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Intrommune Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Intrommune Therapeutics News

Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy

Jun 22, 2022

Amendment to Extend Study Duration to 48 weeks New Maintenance Period Is Designed to Evaluate Safety of INT301 After Long-term Exposure NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics , Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy. The amendment increases the study duration for patients to 48 weeks to include a maintenance period. This maintenance period allows for the evaluation of safety after long term use of INT301. Additionally, the amendment allows for the inclusion of a Double-Blind Placebo Controlled Oral Food Challenge (DBPCOFC) at the end of treatment. The OMEGA Phase 1 Clinical Trial, including the initial results of the DBPCOFC, will inform the dosing regimen and design of future clinical studies. INT301 is a novel peanut desensitization immunotherapy formulated as a fully-functioning toothpaste conveniently administered during a patient’s daily toothbrushing routine. “We continue to make steady progress in the clinical development of INT301 for peanut allergy. We are encouraged by the FDA clearance of this amendment to our ongoing Phase 1 OMEGA Clinical Study, which will now include an evaluation of the long-term safety of INT301 in peanut allergic adults and inform the design of future studies,” said Michael Nelson, CEO, Intrommune Therapeutics. “We are encouraged that most patients remaining in Cohort 2 and Cohort 3 when we received this allowance from the FDA consented to maintenance dosing, even though this requires undergoing an additional oral food challenge. The support and interest we have received from patients and physicians has reassured us that we are developing a product that patients need and want.” Intrommune Therapeutic’s Phase 1 OMEGA Clinical Study is a randomized, double-blind, placebo-controlled study that enrolls adults with peanut allergy in a 3:1 ratio to receive either an escalating dose of INT301 or placebo. Cohort 1 patients started at the lowest dose and were titrated through four increasing doses of INT301. The study groups are blinded to the investigator, patients, and the Intrommune study team. Earlier this year the FDA allowed an amendment to the OMEGA Clinical Study to determine Maximally Tolerated Dose in Cohorts 2 through 4. Cohort 3 is fully enrolled, and to date, no patient on Cohort 1 through 3 has had a significant or even moderate adverse event that is related to the study treatment. All study-related adverse events have been mild and transient. Based on pre-specified criteria, including the safety profile of patients enrolled in Cohorts 1 through 3, the internal Safety Monitoring Committee approved the opening of Cohort 4, starting patients at Dose 4. Phase 1 is designed to help ascertain the highest safe starting dose, which may shorten the up-titration period required to reach INT301 maintenance dosing, reduce the number of office visits required and making the most convenient immunotherapy option even more convenient. About Peanut and Other Food Allergies Food allergies affect more than 220 million people worldwide, including approximately 32 million people in the U.S. Management of food allergies currently focuses on avoidance of exposure to triggering foods, though often such foods, including peanuts, are common ingredients in food products and therefore difficult to avoid. Many people with peanut allergy are accidentally exposed and experience potentially life-threatening reactions, including anaphylaxis, each year. Unfortunately, food allergy remains an area of tremendous unmet medical need. About Oral Mucosal Immunotherapy™ Oral mucosal immunotherapy (OMIT) uses a specially formulated toothpaste to stabilize and deliver allergenic proteins to immunologically active areas of the oral cavity with the greatest potential for allergy desensitization. Success with allergy immunotherapy hinges on consistent exposure of a patient’s immune system to gradually “desensitize” the patient to the specific allergy trigger over time. OMIT presents advantages over other approaches to allergy immunotherapy due to its targeted delivery and simplified administration, which supports the potential for improved adherence. About Intrommune Therapeutics Intrommune , dedicated to improving and protecting the lives of people with food allergy, is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. OMIT is a patient-friendly solution for over 220 million people worldwide, including 32 million people in the U.S., who suffer from life-altering food allergies. Intrommune Therapeutic’s lead product, INT301, has entered Phase 1 clinical trials. All of Phase 1 results along with future studies are intended to support OMIT as being a safe, effective and convenient therapy for patients who suffer from peanut allergy. For more information on Intrommune Therapeutics, please visit http://www.intrommune.com Contact: Cautionary Statement Regarding Forward Looking Statements This release may contain "forward-looking statements." Forward-looking statements are identified by certain words or phrases such as "may," "will," "aim," "will likely result," "believe," "expect," "will continue," "anticipate," "estimate," "intend," "plan," "contemplate," "seek to," "future," "objective," "goal," "project," "should," "will pursue" and similar expressions or variations of such expressions. These forward-looking statements reflect the company's current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the company. The company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release. This release does not contain or constitute an offer to sell or a solicitation of any offer to buy securities in the United States or in any other jurisdiction.

Intrommune Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Intrommune Therapeutics Rank

  • When was Intrommune Therapeutics founded?

    Intrommune Therapeutics was founded in 2015.

  • Where is Intrommune Therapeutics's headquarters?

    Intrommune Therapeutics's headquarters is located at 20 W 125th St., New York.

  • What is Intrommune Therapeutics's latest funding round?

    Intrommune Therapeutics's latest funding round is Series B.

  • How much did Intrommune Therapeutics raise?

    Intrommune Therapeutics raised a total of $220K.

  • Who are the investors of Intrommune Therapeutics?

    Investors of Intrommune Therapeutics include Red Bear Angels and Netcapital.

  • Who are Intrommune Therapeutics's competitors?

    Competitors of Intrommune Therapeutics include DBV Technologies and 1 more.

  • What products does Intrommune Therapeutics offer?

    Intrommune Therapeutics's products include INT301 and 1 more.

You May Also Like

Moonlight Therapeutics Logo
Moonlight Therapeutics

Moonlight Therapeutics develops a targeted therapy that reduces the potential for a severe anaphylactic reaction from accidental exposure.

Alladapt Immunotherapeutics Logo
Alladapt Immunotherapeutics

Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergies. The company’s lead program, ADP101, is being advanced as a broad-spectrum oral immunotherapy treatment to mitigate food allergies triggered by single or multiple proteins from an expansive set of common allergens. Alladapt Immunotherapeutics was founded in 2018 and is based in Menlo Park, California.

DBV Technologies Logo
DBV Technologies

DBV Technologies (NASDAQ: DBVT) is a global, clinical-stage biopharmaceutical company aiming to advance epicutaneous immunotherapy. It is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this class of non-invasive product candidates, the company is dedicated to safely transforming the care of food-allergic patients. DBV Technologies was founded in 2002 and is based in Montrouge, France.

A
Aimmune Therapeutics

Aimmune Therapeutics develops treatments for food allergies using standardized, pharmaceutical-grade food allergens and characterized oral desensitization immunotherapy, or CODIT, system. The CODIT system is built on a foundation of extensive independent scientific research on oral immunotherapy that shows that most patients with food allergies can become desensitized to the food by ingesting their allergens in gradually increasing amounts and then maintaining a steady daily dose thereafter. Aimmune aims to offer standardized product, protocol and support services to protect people with food allergies from accidental exposures by achieving clinically meaningful levels of desensitization to food allergens.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.